Karyopharm Therapeutics Inc.（纳斯达克代码：KPTI）宣布，其针对骨髓纤维化患者的三期Sentry临床试验已成功达到首个共同主要终点。数据显示，接受治疗的患者在脾脏体积缩小方面取得统计学上的显著改善。
该突破性进展为骨髓纤维化治疗领域带来新的希望，标志着Karyopharm在血液恶性肿瘤治疗研发中迈出关键一步。研究人员将继续评估试验的第二个共同主要终点——总症状评分改善情况。
Karyopharm Therapeutics Inc.（纳斯达克代码：KPTI）宣布，其针对骨髓纤维化患者的三期Sentry临床试验已成功达到首个共同主要终点。数据显示，接受治疗的患者在脾脏体积缩小方面取得统计学上的显著改善。
该突破性进展为骨髓纤维化治疗领域带来新的希望，标志着Karyopharm在血液恶性肿瘤治疗研发中迈出关键一步。研究人员将继续评估试验的第二个共同主要终点——总症状评分改善情况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.